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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information provided 
to the EMCDDA by the EU Member States, the candidate countries Croatia and Turkey, and Norway as part of the national 
reporting process.
The most recent Selected issues are:
• Treatment and care for older drug users
• Problem amphetamine and methamphetamine use in Europe
• Trends in injecting drug use in Europe
• Drug offences: sentencing and other outcomes
• Polydrug use: patterns and responses
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website:
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this Selected issue:
• the heads of Reitox national focal points and their staff;
• the services within each Member State that collected the raw data;
• the members of the Management Board and the Scientifi c Committee of the EMCDDA;
• the Publications Offi ce of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of their governments, 
the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at:
http://www.emcdda.europa.eu/about/partners/reitox-network
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7Introduction
Recent estimates suggest that, each year, over 
1 million Europeans receive treatment for problems related 
to the use of illicit drugs (EMCDDA, 2010). Of these, more 
than half receive opioid substitution treatment for problems 
related to opioid drugs, primarily heroin. The current levels 
of provision of drug treatment services in the European 
Union are the result of an expansion of services that has 
taken place during the last two decades. For much of that 
time, services expanded against a background of a growing 
drug problem, and one in which economic conditions were 
largely favourable. Now, however, in an era of cuts in 
government expenditure, managing the costs of treatment 
and ensuring the highest quality and best outcomes for the 
lowest possible cost are priorities.
While measuring and improving drug treatment outcomes 
have been relatively high on the research agenda in recent 
years, the cost of treatment has received far less research 
attention. Addressing this information gap is likely to have a 
number of benefi ts for both decision-makers and treatment 
providers. On the one hand, service providers need 
accurate information on the costs of service provision in 
order to plan the allocation of resources. On the other, 
decision-makers and funders can use such information as a 
means of cost control, for example, by comparing costs of 
similar services or those of alternative providers of similar 
services. Finally, as a part of a fuller economic analysis, 
information on service costs is needed to determine the 
cost-effectiveness of interventions and treatment 
programmes. 
The cost of drug treatment in Europe is looked at from two 
main angles in this Selected issue. First, it presents an 
overview of the main sources of drug treatment funding and 
the fi nancing mechanisms that are employed in European 
countries. The available data are presented on who is 
paying for drug treatment, how funding is organised, and 
how funding is distributed among different treatment 
modalities. This is followed by an analysis of the unit costs of 
different types of drug treatment. Costs related to opioid 
substitution treatment including the costs of substitution 
medication for a number of European countries are 
presented here. This publication keeps a tight focus on the 
cost of drug treatment and does not attempt to undertake a 
broader economic analysis of the healthcare and social 
costs relating to illicit drugs. 
Exploring the cost and fi nancing of drug treatment services in Europe
This Selected issue represents a fi rst attempt to provide a 
European overview of drug treatment costs, and individual 
countries are brought into focus to illustrate specifi c aspects 
of the analysis. This subject is both topical and 
methodologically challenging. The varying availability of 
information as well as the complexity of funding 
arrangements mean that, at best, only very incomplete 
estimates can be made of the costs of (or expenditure on) 
drug treatment in Europe. 
Methods and data sources
The limited available information on cost of treatment in 
Europe comes from two main sources: cost studies, and 
national information on expenditure. The principal sources 
of data for this Selected issue are the Reitox national focal 
points — the EMCDDA’s network of national partners in the 
27 EU Member States, two candidate countries and 
Norway. The national focal points of 13 of these countries 
provided data on drug treatment cost and fi nancing in their 
2010 Reitox national reports. This information varied in 
scope and depth, and the present exploratory analysis is 
based primarily on detailed information from four countries 
— the Czech Republic, Germany, Luxembourg and the 
United Kingdom (England). These data have been 
supplemented by information provided by individual 
national experts as well as fi ndings from the scientifi c 
literature.
Information on the cost of drug treatment was collected 
using EMCDDA defi nitions, focusing on detoxifi cation, 
inpatient and outpatient psychosocial treatment and opioid 
substitution treatment. Efforts were made to avoid including 
expenditure on activities not falling within the working 
defi nitions of drug treatment, such as prevention and 
treatment of alcohol dependence. However, disaggregating 
national data in such a manner was not always possible.
Cost may be defi ned in a number of ways: (a) the amount of 
cash paid for a good or service, that is to say the cash fl ow 
associated with purchasing a good or service; (b) the value 
of the resources used in acquiring a good or service, 
whether paid for or not; or (c) the purchase price of a good 
or service. This Selected issue, while mindful of the broader 
defi nition, considers cash fl ows only, excluding non-paid-for 
resources such as in-kind goods and services (e.g. 
volunteers), full rent, depreciation on donated buildings 
and debt. 
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Drug treatment in Europe
In this Selected issue, data have been collected on the four 
modalities of drug treatment identifi ed by the EMCDDA as 
most frequently used in Europe: detoxifi cation, opioid 
substitution, inpatient and outpatient psychosocial 
interventions. Detoxifi cation is a medically supervised 
intervention to resolve withdrawal symptoms associated with 
chronic drug use, and is sometimes a prerequisite for 
initiating long-term abstinence-based inpatient treatment. 
Typically, detoxifi cation is provided as an inpatient 
intervention in hospitals, specialist treatment centres or 
residential facilities with medical or psychiatric wards; in 
some countries (e.g. Belgium, the Netherlands, the United 
Kingdom), it can be carried out in outpatient facilities 
(Muscat et al., 2010).
In inpatient treatment settings, clients often receive 
individually structured psychosocial treatments and 
participate in activities designed to help them rehabilitate 
into society. Psychosocial treatment based on the therapeutic 
community model is common in a number of countries 
(e.g. the Czech Re public, Italy, Lithuania, Hungary, Poland, 
Portugal). 
The two main modalities of drug treatment in outpatient 
settings in Europe are psychosocial interventions and 
substitution treatment. Psychosocial interventions delivered in 
these settings offer support to users as they attempt to 
manage and overcome their drug problems in the 
community, while allowing them to maintain their 
commitment to family and work. The interventions include 
counselling, motivational enhancement, cognitive 
behavioural therapy, group and family therapy, and 
relapse-prevention. 
Substitution treatment refers to the treatment of drug 
dependence by prescription of a substitute drug with the 
goal of reducing or eliminating the use of a particular 
substance, or of reducing harm and negative social 
consequences. Substitution treatment is based on an 
assessment of the individual’s needs, and is commonly 
supplemented with some form of psychosocial intervention. 
In practice, substitute drugs are available only for heroin; 
no effective substitute substances exist for the other main 
illicit drugs. 
Approaches to estimating cost of treatment
There are two basic approaches for producing a cost of 
treatment estimate: ‘bottom-up’ and ‘top-down’. 
The top-down approach involves examining all costs of a 
treatment programme over a given period of time, and 
allocating resource use according to the number of patients 
treated. This method ensures that all known costs 
attributable to the service are allocated to an activity. For 
many services, only broad totals may be available and 
such a generic approach would be needed. In programmes 
where a variety of activities take place, additional data 
would need to be collected to determine a basis on which 
costs are allocated.
The bottom-up approach involves identifying and 
monitoring each activity and directly measuring the 
relevant resource use. Detailed resource tracing ensures 
that a proportion of the capital cost and overheads are 
allocated to each unit of activity. With good resource 
management systems, this approach can give very accurate 
costs for each client. However, it is likely that this 
methodology will not always result in a total cost fi gure for 
the treatment programme’s activity equal to the actual 
expenditure over the period being examined. For example, 
costs of building and maintenance may be omitted in the 
cost fi gure. 
Bottom-up costing allows more detailed analysis of the 
factors infl uencing resource use than a top-down approach, 
which only produces average fi gures. It can, however, 
involve extensive information systems, which can be costly. 
The desirability of detailed costs information varies with the 
type of intervention. For simple and brief interventions, 
detailed costing is often too elaborate, but it is more 
appropriate for costing the longer-term treatment of clients 
who may be more intensive users of resources. In practice, 
a mixture of methodologies is used with some costs being 
allocated to activities in a top-down approach while other 
resource use can be more accurately traced.
Cost analysis is a prerequisite for full economic evaluations 
in which both the costs and the consequences (outcomes) of 
drug treatment are examined and compared. This type of 
evaluation addresses questions of value for money. 
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In addition to receiving help in specialised drug treatment 
facilities, drug users may also participate in self-help groups 
or receive treatment in primary care and other medical 
settings, including emergency rooms and mental health 
services. Costs of care provided in non-specialised facilities 
are not explored in this publication, with the exception of 
opioid substitution treatment administered through general 
practitioners.
In a recent EMCDDA survey among the 30 national focal 
points, the majority of Member States reported the public 
provision of treatment across the four key modalities 
(Figure 1). At least half of the countries reported the 
availability of the same treatment modalities through private 
providers. Apart from detoxifi cation treatment, non-
governmental organisations are reported as providers of the 
various treatment modalities by at least half of the countries, 
with a focus on psychosocial modalities. Fewer countries 
report the provision of treatment services by general 
practitioners; with substitution treatment the most often cited 
modality for this group of providers. 
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Figure 1: Providers of drug treatment in Europe
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In the following sections, we review the main payers or funders 
of drug treatment services in Europe, before moving on to 
examine mechanisms of payment. Depending on the country, 
the funders of drug treatment services may include public 
sources, private sources and social health insurance. 
Public sources are governments that raise funds through taxes, 
donor grants and loans (Schieber and Akiko, 1997). These 
sources can operate at different administrative levels, from 
national to regional or local. Private sources include donors, 
international or domestic, fi nancing drug treatment through 
grants, loans, and in-kind contributions, as well as individuals 
who pay fees directly to providers of drug treatment services. In 
a number of European countries, healthcare is fi nanced through 
social health insurance, whereby workers and employers are 
obliged to contribute to health insurance funds which fi nance 
drug treatment. Social health insurance programmes may also 
receive government funds for unemployed individuals and other 
groups that are eligible for subsidised contributions. 
In Europe, governments are the main payers for drug treatment, 
providing more than half of the funding in 11 of the 
13 reporting countries (Figure 2). The roles played by the 
various levels of government, however, differ between countries. 
In Portugal, treatment funding is provided solely by the central 
government. In fi ve further cases (Estonia, Greece, Cyprus, 
Luxembourg, the United Kingdom), the central government 
provides more than half of the funding for drug treatment. In 
contrast, local bodies account for all drug treatment funding in 
Denmark, and local or regional bodies account for over half of 
it in Spain and Finland. In the Czech Republic, central and 
lower levels of government provide roughly equal amounts, 
together accounting for more than half of drug treatment 
funding. 
Funding of drug treatment by social health insurance is reported 
by fi ve countries. In two of these (Germany, Slovenia), social 
health insurance is the main funder, while it is a substantial 
funder in three others (the Czech Republic, Austria, 
Luxembourg).
The existence of private sources of funds is reported by a 
number of countries, though only two provide data (the Czech 
Republic, Cyprus). 
The breakdown of drug treatment funding presented here 
must be regarded as a fi rst approximation, and for some 
countries it was diffi cult to identify national fi gures. In many 
cases, data were incomplete, and for some sources there 
was insuffi cient distinction between interventions for different 
types of substance, for example between licit and illicit 
drugs. Other problems included the aggregation of 
treatment expenditure with that of other types of intervention 
(e.g. prevention, social reintegration), and lack of details on 
the intended use of funds. In such scenarios, examination of 
additional documents and analysis at a secondary (e.g. 
regional or service provider) level was needed to yield 
further details. 
The complexity that may be involved in analysing drug 
treatment costs can be illustrated by the examples from 
Germany and Portugal. In Germany, the health system is 
funded by a multiplicity of sources, with data distributed 
across a large number of institutions. In Portugal, although 
drug treatment is fi nanced through the state’s general 
Financing drug treatment
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Source: Reitox national focal points.
Figure 2: Distribution of drug treatment funding by source
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budget, EU Structural and Cohesion Funds are accessed and 
used for specifi c activities, such as drug treatment 
infrastructure development. This mix of national and 
international shared fi nancing, typically with multi-year funds 
committed to buildings and renovation, means that they are 
not necessarily refl ected in each year’s annual budget. 
Drug treatment funding and 
non-governmental organisations
As shown above, there is substantial variation in the 
breakdown between public and private funding of drug 
treatment. The picture becomes more complex with the 
subcontracting of the provision of drug treatment services 
(along with clinical staff training, informing and working 
with the local community) to non-governmental organisations 
(NGOs). This refers to any public purchasing or donor 
fi nancing of services from private providers, both for profi t 
and non-profi t. In 2008, while publicly owned facilities are 
all entirely funded by public sources, NGOs had overall 
considerable but less public funding, in the range of 70 % to 
80 % in Spain, Greece and Luxembourg. 
Luxembourg is unique in that all specialised drug treatment 
is provided through a nationwide network of NGOs, 
fi nancially supported by and accountable to the Ministry of 
Health. In Finland, NGOs or private service providers 
account for more than half of specialised drug treatment 
provided in the country (Kekki and Partanen, 2008). 
In other countries, although NGOs play an important part in 
drug treatment, their contribution to the overall provision of 
service is not well documented. This is the case in England, 
where treatment provided by NGOs is paid for by central 
and local governments. In parts of Germany (e.g. the city 
states), Länders co-fi nance NGOs by distributing ‘subject-
related lump sums’ for the provision of psychosocial 
interventions to clients in opioid substitution treatment. 
Typically, in countries reporting such forms of target and 
impact-oriented distribution and use of resources, these 
practices are supported by framework agreements between 
individual ministries and local NGOs.
Healthcare fi nancing: the role of social security 
In Europe, there are three main sources of healthcare 
fi nancing: households, employers and the state. The latter 
includes the general government, at all levels, and social 
security. 
Social security is a social insurance programme, imposed 
by governments for the purpose of providing social benefi ts 
to the community. Its programmes cover a wide variety of 
areas including: benefi ts for old age, invalidity, maternity, 
work injury, unemployment and healthcare (Eurostat, 
2008). There is not necessarily a direct link between 
contributions paid by an individual and benefi ts received. 
In the area of health, the mix of private, public expenditure 
and social contributions varies widely from country to 
country. In the European Union, healthcare is primarily 
funded by the public sector (73.6 % of total expenditure in 
2008, on average) (OECD, 2010), with social security 
accounting for slightly more than general government 
funds, on average. 
The data show that public sources fund most of the 
healthcare expenditure in Europe. However, they do not 
play a dominant role in every area. While the public sector 
paid an average of 82 % of medical services (e.g. 
outpatient services) in 2008, it only funded about 50 % of 
medical goods (e.g. pharmaceuticals).
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Payment mechanisms 
Having examined the main payers or funders of drug 
treatment services in Europe, below we review another 
feature that can be used to describe the interaction between 
funders and drug treatment providers: the mechanisms of 
payment.
Prospective annual budgets for providers are frequently used 
as the mechanism for disbursing funds to public drug 
treatment providers — either directly from the Ministry of 
Health, or through local government administrations to their 
network of provider organisations in the form of grants. 
Under such arrangements, in England, the annual pooled 
treatment budget is calculated and allocated to local 
services by taking into account, among others, factors such 
as caseload complexity of the local treatment population 
and their specifi c problems, and other drug users.
Case-based payments combine the estimated costs 
associated with all drug treatment interventions typically 
involved in the treatment of drug problems and result in a set 
payment for each case (patient) treatment episode, 
according to a predetermined payment schedule based on 
the estimated total cost. Inpatient detoxifi cation in hospitals 
in Germany and Austria is paid for according to this 
principle. 
In addition to receiving public funding, NGOs may also 
make their own fi nancial contribution to the costs of drug 
treatment. Examples of this include the use of church tax in 
Germany, and funds from enterprises connected to drug 
treatment programmes, where treatment clients produce 
goods (Greece) or provide services in the local community 
(Austria). In addition to funds derived from the state and 
their own sources, NGO-run programmes may charge 
clients fees, and they may receive donations in cash and 
other assets (e.g. buildings, land).
Administrative level for drug 
treatment funding
Separate from the question of who funds drug treatments, is 
the administrative level at which funds are managed. Despite 
the diversity of ways in which drug treatments are fi nanced 
from a range of public and private sources, in most of the 
13 countries, funds are managed at national level (Table 1). 
The exceptions are Finland, which reports no national-level 
management of these funds, and Germany, where only 
funds for model treatment projects (e.g. treatment research) 
are managed at this level. Administration of funds at local 
government level is reported by seven countries, while four 
countries administer funds at the regional or provincial level. 
In half of the 13 countries, funds are managed at more than 
one level of government.
Table 1: Levels of government at which drug treatment funding is managed
National Regional Local 
Czech Republic X X X
Denmark X
Germany Model projects only X X
Estonia X
Greece X
Spain X X X
Cyprus X
Luxembourg X
Austria X X X
Portugal X
Slovenia X X
Finland X
United Kingdom (England) X X
Source: Reitox national focal points.
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In some countries, treatment providers are offered cost-
based retrospective reimbursements, based on the providers’ 
costs or set according to the ‘prevailing’ charge in a local 
community. In some Austrian provinces, for instance, 
non-hospital inpatient drug treatment programmes can be 
reimbursed for the daily costs of the individual services 
delivered to patients, subject to case-by-case approval.
Finally, in several countries, individual treatment providers 
are paid on a fee-for-service basis. For example, in England, 
community pharmacies that offer their services to the 
National Health Service within the supervised consumption 
scheme are retrospectively reimbursed from a secondary 
care specialist budget, based on the number of prescriptions 
dispensed (NTA, 2006).
Countries report changes that could have important 
implications for the funding and delivery of drug services in 
the future. For example, in England, payment-by-results pilot 
projects are being introduced in drug treatment funding. This 
scheme aims to give providers from all sectors incentives for 
better performance (see the box on this page).
Payment by results approaches 
The United Kingdom’s National Treatment Agency (NTA) 
for Substance Misuse (England only), with involvement from 
a number of government departments, is testing a range of 
new approaches for the commissioning and delivery of 
drug treatment and recovery systems that reward 
achievement of outcomes. 
The current funding system pays service providers an 
agreed budget, regardless of outcomes. Under the pilot 
scheme, providers of drug treatment will be paid, after they 
have provided the service, on the basis of the results they 
achieve in terms of long-term recovery. They are 
encouraged to support all treatment clients, including those 
in contact with the criminal justice system and people 
dependent on alcohol. 
Payment by results for drug treatment services is based on 
outcome measures such as leaving treatment in a planned 
way, being drug-free and back to work, and improved 
health and well-being. To achieve this, the scheme aims to 
give clients the full range of support services to sustain 
recovery and integrate into society. A recent report argued, 
however, that this will pose ‘enormous practical challenges 
for those delivering services and for managing the system’, 
as a wide range of providers will need to cooperate to 
address multiple clients’ needs (UKDPC, 2011). 
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Efforts to quantify European expenditure on drug treatment 
are still at an early stage. Two main advances in data 
collection are required in order to be able to describe drug 
treatment expenditure in the European Union. The fi rst of 
these concerns gathering comprehensive information on 
drug treatment expenditure; the second concerns expanding 
the collection of data on drug treatment clients to include the 
total in-treatment population. In each of these areas, 
appropriate methodologies that can be used by all Member 
States are needed. 
From the limited information available for nine European 
countries, it can be roughly estimated that annual 
expenditure on drug treatment in these Member States 
equates to between EUR 1 and EUR 20 per head of the 
adult population. The data on which these estimates are 
based, while mostly referring to the years 2007–09, also 
include fi gures from 1999 and 2002. Furthermore, the 
available data are insuffi cient to estimate the total cost of 
drug treatment in Europe. For seven countries, estimates of 
treatment expenditure and the population of treatment clients 
allow the average expenditure per client to be calculated. 
For these seven countries, the average annual expenditure 
for drug treatment ranges from EUR 550 to EUR 4 900 per 
client — with the large difference potentially infl uenced by 
the extent of utilisation of different types of treatment, each 
of which has a different cost associated with it.
Estimating expenditure on drug treatment in Europe
Distribution of funding 
by drug treatment modality
Having, in previous sections, examined where drug 
treatment funds originate, here the focus is on the division of 
funding between the modalities of major drug treatment 
(detoxifi cation, psychosocial inpatient, psychosocial 
outpatient, and opioid substitution treatment). 
Each of the four countries for which data are available 
reports a different distribution of funding across the 
treatment modalities (Figure 3). In the United Kingdom and 
Germany, more than two-thirds and just over a half of the 
respective available treatment funds are allocated to the 
provision of opioid substitution treatment, though in the 
Czech Republic and Luxembourg, this modality accounts for 
less than 7 % of the available funds. In the Czech Republic, 
psychosocial treatment consumes the greater part of 
treatment resources, with inpatient and outpatient services 
each receiving about a third of the funding. In Luxembourg, 
the emphasis is on outpatient psychosocial treatment, which 
accounts for half of the treatment budget, and detoxifi cation 
(17 %). In all four reporting countries, detoxifi cation 
treatment is reported to receive not more than 20 % of drug 
treatment funds.
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Distribution of funding proportions by treatment modality 
can be exemplifi ed by Germany. Detoxifi cation costs include 
costs related to the provision of medical treatment and 
detoxifi cation in both general hospital units and in 
psychiatric wards, as reported by Mostardt et al. (2009). 
Although some of this expenditure may be related to other 
aspects of addiction treatment, it is estimated that at least 
80 % is related to initial medical treatment and 
detoxifi cation. Data are not available on the total cost of 
substitution treatment in Germany. Nonetheless, an initial 
calculation, based on the cost of visits to general 
practitioners providing substitution treatment (Mostardt et al., 
2009) and an 8 % indirect cost, yields an estimate of 
EUR 844 million (EUR 801 million, price year 2006) (1) as 
the annual cost of opioid substitution treatment. Expenditure 
of about EUR 387 million (EUR 367 million, price year 
2006) on psychosocial outpatient treatment is indicative of 
the cost of providing outpatient counselling to users 
dependent on opioids, cannabis and stimulants (2); 
expenditure on psychosocial inpatient treatment was 
estimated at EUR 118 (EUR 112 million, price year 2006) 
(Mostardt et al., 2009).
The observed differences between the reporting Member 
States might refl ect different client needs as well as 
differences in treatment philosophies and methodological 
issues. In addition, policy contexts in each of the countries 
might be guiding decisions about resource allocation for 
different types of drug treatment. Acknowledging the data 
limitations, these results provide an illustration of the 
differences that exist between countries in relation to drug 
treatment resource division.
A proportion of the reported funding for drug treatment in 
Luxembourg is allocated to the treatment abroad of 
nationals, in therapeutic interventions unavailable in the 
country — identifi ed as ‘other’ in Figure 3. For Luxembourg, 
data on substitution treatment costs refer to interventions 
provided in non-specialist settings. 
(1) Expenditure fi gures are adjusted for 2009, using consumer price indices for Germany (OECD, 2010).
(2)  Additional funding for psychosocial outpatient treatment is provided by local governments but these resources are not accounted 
for as data were unavailable.
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NB:  Germany: the percentages are estimations based on available data 
that are incomplete.
Source: Reitox focal points. For Germany: Mostardt et al., 2009.
Figure 3: Distribution of funding by treatment modality
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Having examined the distribution of funding across treatment 
modalities, this section focuses on the unit costs for the main 
treatment modalities. In treatment studies, unit costs are 
generally presented as the daily cost of providing a patient 
with a particular type of treatment. Factors such as treatment 
settings and treatment interventions that are typically 
employed in Europe will have an impact on unit costs. The 
data available for unit costing are very limited for all types 
of treatment modality, though less so for opioid substitution 
treatment. The data used here come from national focal 
points and studies published in the scientifi c literature. 
Clinical studies may include costs that are imposed on 
providers by research protocols and may therefore be 
higher than the costs in everyday clinical practice. To allow 
more direct comparisons, all unit costs have been adjusted 
to 2009 prices, using country-specifi c consumer price 
indices (CPI) (OECD, 2010). Cost fi gures from the original 
price year are reported in brackets.
Detoxification
For this analysis, data on detoxifi cation are available only 
from two countries, where inpatient detoxifi cation is 
provided at a cost of EUR 199 (England) and EUR 247 
(Germany) per patient per day. Studies on the costs of 
inpatient detoxifi cation in Europe are rarely published in the 
literature. The few studies reviewed here concern the United 
Kingdom (England) and most are based on data that are at 
least 10 years old. The National Treatment Outcomes 
Research Study (NTORS) in England, based on data from 
eight agencies, estimated the cost of providing inpatient 
detoxifi cation at between EUR 110 (EUR 93, price year 
1999/2000) and EUR 303 (EUR 254, price year 
1999/2000) per patient per day, with an average of about 
EUR 206 (EUR 174, price year 1999/2000) per patient per 
day (Godfrey et al., 2004). The follow-up to NTORS, the 
Drug Treatment Outcome Research Study (DTORS), based on 
283 patients in inpatient treatment (detoxifi cation) in 
England, reported a cost of EUR 182 (EUR 172, price year 
2006/07) per patient per day (Davies et al., 2009). Also in 
England, Gossop and Strang (2000) compared the costs of 
opioid detoxifi cation in two different settings: a specialist 
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inpatient drug dependence unit and a drug dependence 
outpatient clinic. Detoxifi cation provided in inpatient settings 
was estimated to cost EUR 200 (EUR 168, price year 
1999/2000) per patient per day, compared to EUR 8 
(EUR 7, price year 1999/2000) per patient per day for the 
same treatment in outpatient settings. The authors of this 
study took their calculations one stage further, and looked at 
cost-effectiveness. They adjusted the costs of the treatment 
packages according to inpatient and outpatient 
detoxifi cation completion as measured in earlier trials 
(Gossop et al., 1986; Strang et al., 1997). With successful 
detoxifi cation completion rates of 81 % among inpatient 
clients and 17 % among outpatient clients, inpatient 
detoxifi cation was found to be the more cost-effective of the 
two approaches.
Inpatient and outpatient psychosocial 
treatment
Information on the overall costs or the unit costs of 
psychosocial treatment is available for the Czech Republic, 
Germany, Sweden, the United Kingdom and Norway. Based 
on national focal point data for 2008/09, in the Czech 
Republic, the total annual cost of inpatient treatment and 
residential rehabilitation was EUR 10 million, of which 
EUR 7 million was attributed to inpatient treatment and 
EUR 3 million to residential rehabilitation in therapeutic 
communities. In Germany, the annual cost of psychosocial 
inpatient treatment and rehabilitation is reported at about 
EUR 118 million (EUR 112 million, price year 2006) 
(Mostardt et al., 2009), however, there are no activity data 
to estimate daily cost per treated client. 
England’s NTORS showed cost estimates, based on a variety 
of national sources and specifi c data collection for the study, 
ranging from EUR 59 (EUR 50, 1999/2000 prices) to 
EUR 216 (EUR 181, price year 1999/2000) per resident per 
day across 15 agencies offering residential rehabilitation 
(Godfrey et al., 2004). More recent cost analysis of 
residential rehabilitation provided to 261 participants in 
DTORS determined a cost of EUR 56 (EUR 53, price year 
2006/07) per resident per day (Davies et al., 2009). 
Another English study reported daily costs varying from 
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EUR 79 (EUR 75, price year 2007) to EUR 288 (EUR 272, 
price year 2007) per resident across 11 residential 
rehabilitation units (Curtis, 2008). An estimate for Sweden 
puts the average cost of residential care in that country at 
EUR 404 (EUR 369, price year 2002) per patient per day 
(Ramsteadt, 2006). In Norway, the estimated cost of 
residential rehabilitation is at EUR 234 (EUR 202, price year 
2001) (Melberg et al., 2003). The Czech Republic and 
Germany provided overall cost estimates for outpatient 
psychosocial treatment. Based on national focal point data 
for 2008/09, the annual cost of psychosocial outpatient 
treatment in the Czech Republic is estimated at about 
EUR 4 million. For Germany, Mostardt et al. (2009) report 
the cost of psychosocial outpatient treatment at about 
EUR 387 million (EUR 367 million, price year 2006). 
Opioid substitution treatment
Two countries provided unit cost data for substitution 
treatment. In England, prescription of opioid substitution 
drugs by specialist services is estimated to cost EUR 10 per 
patient per day. Luxembourg reports unit cost data for 
substitution treatment prescribed through general 
practitioners to be EUR 7 per patient per day. 
From published studies, it is possible to extract additional 
data on unit costs. In England, a research study, based on 
401 clients from seven clinics specialising in substitution 
treatment, estimated the range of costs of ‘treatment as 
usual’ (Raistrick et al., 2007). The average total cost of 
treatment per patient per day was EUR 3 (EUR 3, price year 
2007), excluding the cost of prescribed drugs, and EUR 6 
(EUR 5, price year 2007) including prescribed drugs. The 
study found that among the key factors infl uencing treatment 
costs across agencies were the complexity of the case mix, 
the amount of drugs prescribed, and the gender mix. In 
England, methadone maintenance was estimated to cost 
between EUR 2 (EUR 2, price year 2007) and EUR 24 
(EUR 22, price year 2007) per patient per day in the 
15 programmes studied (Curtis, 2008), while the DTORS 
research team, reported specialist prescribing at EUR 18 
(EUR 17, price year 2006/07) per patient per day (Davies 
et al., 2009).
In Spain, Martinez-Raga et al. (2009) reported estimates of 
EUR 4 (EUR 4, price year 2004) per patient per day in 
methadone maintenance treatment and EUR 5 (EUR 5, price 
year 2004) per patient per day in buprenorphine 
maintenance treatment. As these estimates exclude 
medication costs, they are not full unit costs. In Lithuania, 
Vanagas et al. (2010), based on 102 treatment clients, 
estimated the cost of methadone maintenance treatment at 
EUR 4 per patient per day (2004 prices, no CPI identifi ed). 
In Germany, the unit cost of oral methadone maintenance 
treatment (3) was estimated at EUR 10 (EUR 9, price year 
2006) per client per day or EUR 3 490 (EUR 3 314, price 
year 2006) for the 12 month trial period, of which the cost 
of methadone accounted for about 12 % (von der 
Schulenburg and Claes, 2006). An estimate for Norway 
puts the average cost of methadone substitution treatment in 
that country at EUR 37 (EUR 32, price year 2001) per 
patient per day (Melberg et al., 2003).
The unit cost estimates for opioid substitution treatment with 
methadone reviewed here range from EUR 2 to EUR 37 per 
patient per day. This variation may refl ect differences in one 
or more of several possible factors: national and regional drug 
situations and treatment systems, the case mix of patients, year 
of data collection, and inclusion of medication cost.
Components of substitution treatment cost
In this section, the cost of substitution treatment with oral 
medication (methadone and buprenorphine) will be 
explored in more depth. Available substitution treatment cost 
data are broken down into three cost categories (Figure 4): 
labour costs, including pay and employer contributions; 
non-pay costs, including medications; and indirect costs, 
such as rent and energy. 
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NB:  For the Czech Republic, the fi gures given represent the costs for the treatment 
facilities. Private costs for substitution drugs are not included in the data.
Source: Reitox national focal points.
Figure 4: Components of opioid substitution treatment cost
(3) Calculated in the context of the German heroin-assisted treatment model project, based on 200 treatment clients.
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methodology adopted for the Health Technology Assessment 
Programme Report in the United Kingdom (Connock et al., 
2007). 
The prices per milligram of medication were then examined 
for a mean daily dose of methadone and buprenorphine 
(the unit), which is based on expert estimation (unless stated 
otherwise) for each of the reporting countries, to arrive at 
the daily medication cost per patient (unit cost) in oral 
methadone and buprenorphine treatment. Both the prices of 
medications and unit costs vary considerably and, per 
milligram, methadone is much cheaper (EUR 0.006 to 0.05) 
than buprenorphine (EUR 0.23 to 1.09) (Table 2). 
Comparison with the costs of supervised 
injectable methadone 
Within the substitute prescribing modality, using injectable 
methadone ampoules is another prescribing option, 
reserved in England for patients who do not respond to oral 
substitute drug treatment. Compared with oral substitution 
treatment, the provision of injectable methadone 
maintenance treatment is more expensive. This is primarily 
due to high medication and staff costs. Strang et al. (2000) 
estimated a daily cost of supervised injectable methadone 
provision at EUR 18 (EUR 15, price year 2000) per patient 
per day, based on a sample of 39 heroin users randomly 
allocated to receive oral or injectable methadone treatment. 
In the same trial, the unit cost of opioid substitution treatment 
was calculated to be EUR 4 (EUR 3, price year 2000).
Labour costs are the largest component of opioid substitution 
costs, accounting for almost half (48 %) of all expenditure 
on substitution treatment in England, and for over half in the 
rest of reporting countries. Non-pay elements, predominantly 
medications, account for about one-third of the overall cost 
of opioid substitution prescription through specialist 
agencies. Also included in this category are costs for other 
medical materials and for laboratory testing in order to 
monitor illicit drug use. Indirect costs such as overheads 
accounted for, on average, about 15 % of the overall costs 
of substitution treatment.
Cost of opioid substitution medications
In the data presented so far, the cost of substitution 
medication is hidden within the broader category of direct 
medical costs. Yet, as both methadone and buprenorphine 
are commonly used in Europe as opioid substitution 
medications, their costs deserve closer inspection. 
Oral methadone mixture is available in the participating 
countries as a 1 mg/ml preparation (100 ml bottle), 
2 mg/ml (500 ml bottle), and in a concentrated form 
(10 mg/ml). For the purposes of the calculation of oral 
methadone cost, in the countries where more than one 
methadone preparation was available on the market, the 
most economical one has been selected. For buprenorphine, 
which is available in tablet form, the price of 2 mg tablets 
rather than 8 mg tablets was used to calculate the cost of 
the medication (4). This approach is in line with the 
(4) The calculation for the Czech Republic is based on the price of 8 mg tablets, as these are the more common form of buprenorphine used in that country.
Table 2: Costs of oral opioid substitution medication
Country Methadone (per patient treated) Buprenorphine (per patient treated)
Average daily 
dose (mg)
Price 
(EUR/mg)
Unit cost 
(EUR/day)
Average daily 
dose (mg)
Price 
(EUR/mg)
Unit cost 
(EUR/day)
Czech Republic 90 0.006 0.5 6 1.05 6.3
Germany 72.6 0.02 1.5 7.1 1.09 7.7
Greece 60 0.03 1.8 8 0.23 1.8
Cyprus n.a. 12 0.5–1.0 6.0–12.0
Finland 102 0.05 5.3 16 0.95 15.2
United Kingdom 
(England) 56.3 0.01 0.7 7.9 0.46 3.6
NB: Unit cost is the cost of the average daily dose of a medication for a patient; n.a., data not available. 
Source:  Reitox national focal points. Dose data for England are based on Strang et al. (2007). Dose data for Germany are based on unpublished information.
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patients with high levels of need (EMCDDA, in press). 
Irrespective of treatment choice, health and social care 
systems would be likely to incur high levels of costs in 
providing for the needs of these clients.
Heroin-assisted treatment 
In addition to the data on the cost of the four main treatment 
modalities, information is available on the cost of heroin-
assisted treatment, a specialist intervention currently part of 
routine clinical practice in four EU Member States (Denmark, 
Germany, the Netherlands, the United Kingdom (England)) 
and Switzerland. Heroin-assisted treatment includes the 
provision of injectable doses of pharmaceutical heroin, 
closely supervised in clinical settings, to patients who have 
not responded to standard treatments, such as substitution 
treatment with oral medication.
In Switzerland, Gutzwiller and Steffen (2000) estimated the 
cost of heroin-assisted treatment service provision in large 
(232 patients), medium (150 patients) and small-scale 
(70 patients) supervised injectable maintenance clinics. The 
annual costs per patient were EUR 12 694 (EUR 11 300, 
price year 1995), EUR 14 379 (EUR 12 800, price year 
1995) and EUR 14 492 (EUR 12 900, price year 1995) 
respectively — an average of EUR 37 (EUR 33) per patient 
per day or EUR 13 593 per year (EUR 12 100, price year 
1995) for all clinics. 
In the Netherlands, Dijkgraaf et al. (2005) estimated a cost 
of EUR 56 (EUR 48, price year 2001) per patient per day 
(an annual cost of EUR 20 410 (EUR 17 634, price year 
2001). Similarly, in the context of the German heroin-
assisted treatment model project, the average daily cost 
amounted to EUR 52 per patient (EUR 50, price year 2006) 
or EUR 19 020 per year (EUR 18 060, price year 2006). 
Injectable heroin treatment has been estimated to cost 
between three to 10 times as much as oral substitution 
treatment, depending o n whether some costs components or 
the total treatment costs are accounted for (Strang et al., 
2009). Unit costs of the Dutch injectable heroin programme 
were reported to be 12 times as expensive as a programme 
based on oral methadone (Dijkgraaf et al., 2005). This was 
mainly due to the need for new clinical premises and clinical 
supervision of patients injecting up to three times a day. The 
cost of injectable heroin, in particular, may be a prohibitive 
factor to commencing treatment and to long-term 
prescribing. Nonetheless, in all countries that have 
introduced heroin-assisted treatment, it is recognised that 
injectable maintenance drug treatment should be targeted at 
Cost analysis and best practice 
One of the barriers to the implementation of evidence-
based interventions is the concern about possible costs 
increase (Eccles et al., 2000). The adoption of an 
evidence-based approach can be resource-intensive, 
especially if evaluation studies are performed (Guyatt 
et al., 2008). Conversely, evidence-based health decisions 
reduce the costs accrued by ineffective treatment and 
medications. In addition, the use of evidence-based care, 
over time, leads to improved client health and reduces 
further complications and need for treatment.
Treatment costs analyses may also facilitate sustainable 
choices in terms of best practice adoption and 
implementation. The Cochrane Library, a well-known source 
of evidence of effectiveness, contains a database of 
economic evaluations, including cost effectiveness 
evaluations of opioid substitution treatment with 
buprenorphine, buprenorphine-naloxone, and methadone, 
as well as evaluations of heroin-assisted treatment. No 
differences in terms of cost-effectiveness were observed 
between methadone and buprenorphine (with or without 
naloxone) (Doran, 2005); and the provision of methadone 
in prison was not more expensive than in the community 
(Warren et al., 2006). Methadone provision on a lifelong 
basis (consistent with the chronic disease approach) was 
studied with a multi-domain model fi nding an overall 
benefi t for this treatment (Zarkin et al., 2005). While the 
above-mentioned studies were judged to have limitations, a 
study on co-prescription of heroin and methadone versus 
methadone only for maintenance treatment (Dijkgraaf et al., 
2005) was considered appropriately performed and 
reported. To assess the value for money of the interventions, 
data from a randomised controlled trial conducted in the 
Netherlands (van den Brink et al., 2003) were analysed 
using a measure of disease burden that takes into account 
the quality and quantity of years lived. The analysis also 
incorporated the costs to society due to criminal activities, 
and concluded that co-prescribed heroin treatment 
produced a substantial cost saving.
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This exploratory study illustrates the need both for the 
development of common approaches in studies of treatment 
costs and funding and for more countries to undertake 
research in this area. The national estimates that are 
available are diffi cult to compare, as each of them includes 
different elements; and making comparisons between 
different studies, even those carried out in the same country, 
can be challenging because of differences in methodology. 
A number of conclusions do emerge from this exploratory 
study. One of these is that labour appears to be a main cost 
component of substitution treatment, accounting for about 
half of the total expenditure. Staff costs differ between 
countries and in other forms of treatment they can be 
expected to represent different proportions of the overall 
cost. And, even within the same treatment modality, 
differences in therapeutic practices may result in different 
costs. This fi nding is important in highlighting the need to 
consider the national context and delivery practices when 
evaluating the cost-effectiveness of treatment modalities. 
In Europe, drug treatment is fi nanced mainly by public 
funding, though in a few countries social health insurance 
systems are important funders. Countries differ, however, in 
the levels of government at which funds are disbursed and 
managed. In the majority of the 13 Member States 
providing information, drug treatment is funded nationally, 
though local or regional funding is prominent in a number of 
countries. There is also variation within individual countries 
with regard to the organisation of fi nancing for drug 
treatment. 
In terms of unit costs (per person per day) across treatment 
modalities, there are clear differences between the treatment 
types. The highest unit costs are reported for inpatient 
modalities. The unit cost of inpatient psychosocial treatment 
is estimated to range from EUR 59 to EUR 404 per patient 
per day, with Sweden reporting the highest unit cost for this 
treatment. Detoxifi cation carried out in inpatient settings is 
reported to cost between EUR 110 and EUR 303, with both 
the highest and the lowest estimates referring to treatment 
centres in the United Kingdom. Oral substitution treatment 
with methadone is reported to cost the least of the other 
treatment modalities, its unit cost ranging EUR 2 to about 
Conclusions
EUR 37 per patient per day, with the highest cost estimated 
in Norway. Although the unit costs of opioid substitution 
treatment are lower than those of the three other treatment 
modalities, due to the widespread use of this modality, the 
overall annual expenditure of reporting countries on opioid 
substitution treatment is higher than their annual expenditure 
for other treatment types.
The daily cost of substitution medication differs between 
countries by a factor of over seven. For both methadone and 
buprenorphine, the highest price was calculated for Finland. 
This was due to the high dose size reported in this country 
combined with the high price of the medications. In four of 
the fi ve countries reporting price data for both medications, 
the cost of a daily dose of methadone was considerably 
lower than that of buprenorphine. Personnel costs — for 
wages, extra allowances, or management and 
administration — accounted for the greatest proportion of 
opioid substitution treatment costs. This is likely to be the 
case in other treatment modalities, and has been 
documented in the area of heroin-assisted treatment (with 
supervised injectable doses of pharmaceutical heroin) in 
Switzerland (Gutzwiller and Steffen, 2000). Knowledge 
about labour costs is relevant to resource planning and in 
exploring what options might be available for containing or 
minimising costs while maintaining effectiveness. 
In attempting to answer questions about the costs associated 
with providing specialised drug treatment in Europe, this 
Selected issue encountered problems related to data quality 
and availability. In general, the data provided by Member 
States was of varying quality. To a large extent, this is due to 
the diffi culty of retrieving comprehensive data from often 
complex funding streams. Potentially, the most useful sources 
of information include budgets and reports from national 
governments and local or regional authorities, which label 
expenditure according to the main areas of activity, 
including drug treatment. Few countries, however, were able 
to provide such data. Other problems included the paucity 
of data for certain areas of drug treatment and limited 
availability of disaggregated data. In addition, the cost data 
analysed here include data both from treatment studies and 
from cost studies. This is likely to have contributed to some of 
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the variability, as treatment delivered in a research context 
generally has a higher unit cost compared to routine 
treatment. In terms of the future, the development of a set of 
data collection instruments that are modality-specifi c and 
easy to use is a prerequisite for the gathering of comparable 
cost data within Europe. 
Costs are infl uenced by resource use, thus it is unsurprising 
that the cost of treatment differs across the various treatment 
types. Treatment in inpatient settings should use more 
resources than that provided in outpatient settings. Opioid 
substitution treatment is cheaper than the other modalities on 
a unit cost basis, but the length of treatment may be 
open-ended. In addition, client populations utilising the 
different treatment modalities have varying drug use 
problems and health characteristics, requiring different levels 
of resources. 
Meeting the challenge of containing cost, while ensuring 
that adequate access and quality of treatment are not 
compromised, is being explored via therapies delivered with 
a lesser degree of direct clinician involvement. A recent 
review (Newman et al., 2011) of computerised self-
administered therapy and traditional therapies with various 
degrees of therapist involvement for drug addiction 
established the effi cacy of self-administered and 
predominantly self-help computer-based cognitive and 
behavioural interventions, although some therapist contact 
was important for greater and more sustained outcomes. 
Innovative technology-based treatments are often cited as 
potentially low-cost alternatives, but this benefi t is yet to be 
documented.
Similarly, addiction mutual-aid groups have the potential to 
help users recover from dependence at low cost. However, 
despite their long history (White, 2004) and wide use, 
relatively little controlled research has been conducted into 
the effectiveness of these groups, compared to other 
addiction treatments. Furthermore, of the existing research 
(for a review, see Humphreys, 2004), mostly conducted in 
the USA, the focus is almost exclusively on Alcoholics 
Anonymous and, to a lesser extent, on adaptations of their 
twelve-step programme, for example Narcotics Anonymous 
and Cocaine Anonymous. At a time of cuts in government 
spending across Europe, which may affect drug treatment 
budgets, insights are needed into the potential role of 
groups such as these in addiction treatment systems. 
Finally, although it was beyond the scope of this Selected 
issue to explore what society receives in return for public 
expenditure on drug treatment, this information is needed to 
evaluate the cost–benefi t relationship of drug treatment. 
European studies such as England’s National Treatment 
Outcome Research Study (Gossop et al., 1998, 2000, 
2003; Godfrey et al., 2004), Drug Treatment Outcome 
Research Study (Davies et al., 2009) and full economic 
evaluations of heroin-assisted treatment in Germany (von der 
Schulenburg and Claes, 2006), the Netherlands (Dijkgraaf 
et al., 1998) and Switzerland (Gutzwiller and Steffen, 
2000) have examined treatment use and outcomes in these 
countries. When the costs of treatment in these and other 
studies are compared to the social benefi ts gained from 
treatment, including decreases in crime and costs of social 
care and healthcare, the fi ndings are unvarying: treatment is 
cost-benefi cial from the societal perspective. 
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